Edition:
United States

Alder Biopharmaceuticals Inc (ALDR.OQ)

ALDR.OQ on NASDAQ Stock Exchange Global Market

10.85USD
2:23pm EST
Change (% chg)

$0.15 (+1.40%)
Prev Close
$10.70
Open
$10.75
Day's High
$10.90
Day's Low
$10.65
Volume
144,695
Avg. Vol
240,221
52-wk High
$25.40
52-wk Low
$8.68

Latest Key Developments (Source: Significant Developments)

Alder Biopharmaceuticals Q3 loss per share $0.92
Tuesday, 7 Nov 2017 04:23pm EST 

Nov 7 (Reuters) - Alder Biopharmaceuticals Inc :Alder biopharmaceuticals announces third quarter 2017 financial and operating results.Q3 loss per share $0.92.Q3 earnings per share view $-1.17 -- Thomson Reuters I/B/E/S.Alder Biopharmaceuticals Inc - ‍eptinezumab biologics license application (BLA) submission on track for 2h18​.Alder Biopharmaceuticals Inc - ‍promise 2 pivotal trial completed enrollment and top-line data on track for 1h18​.Alder-Sees available cash & cash equivalents, short-term investments to be sufficient for projected requirements through late 2018/early 2019​‍​.  Full Article

Alder Biopharmaceuticals Q2 loss per share $1.48
Tuesday, 8 Aug 2017 04:05pm EDT 

Aug 8 (Reuters) - Alder Biopharmaceuticals Inc :Alder Biopharmaceuticals announces second quarter 2017 financial and operating results.Q2 loss per share $1.48.Q2 earnings per share view $-1.61 -- Thomson Reuters I/B/E/S.  Full Article

Alder Biopharmaceuticals says public offering of 15 mln common shares priced at $10 per share
Wednesday, 12 Jul 2017 06:54pm EDT 

July 12 (Reuters) - Alder Biopharmaceuticals Inc :Alder biopharmaceuticals, inc. Prices public offering of common stock.Says public offering of 15.0 million common shares priced at $10.00per share.  Full Article

Alder Biopharmaceuticals announces commencement of public offering of common stock
Tuesday, 11 Jul 2017 04:28pm EDT 

July 11 (Reuters) - Alder Biopharmaceuticals Inc :Alder Biopharmaceuticals, Inc. announces commencement of public offering of common stock.Alder Biopharmaceuticals Inc - Intends to offer and sell, 12.5 million shares of its common stock in an underwritten public offering.Alder Biopharmaceuticals - Intends to use net proceeds from offering, to fund continued development of eptinezumab, among the others.  Full Article

Alder Biopharmaceuticals announces positive eptinezumab phase 3 results
Tuesday, 27 Jun 2017 07:00am EDT 

June 27 (Reuters) - Alder Biopharmaceuticals Inc :Alder Biopharmaceuticals announces positive eptinezumab phase 3 results for prevention of frequent episodic migraine.Says ‍​pivotal promise 1 top-line results show eptinezumab met primary and key secondary endpoints.Says beginning day 1 after first dose, significant reduction in proportion of patients experiencing migraine.Says average of 1 in 5 patients had no migraines in any given month over months 1 through 6.Says Promise 1 met the primary endpoint, that is highly statistically significant reductions in monthly migraine days.enrollment is on track for Promise 2; remains on track to submit BLA with FDA in second half of 2018.  Full Article

Alder Biopharmaceuticals says presentation of positive data from Phase 2B clinical trial evaluating Eptinezumab for prevention of migraine
Friday, 28 Apr 2017 01:24pm EDT 

April 28 (Reuters) - Alder Biopharmaceuticals Inc :Eptinezumab emerging clinical profile suggests migraine preventative benefit achieved as soon as 24-48 hours after single infusion.Single administration of Eptinezumab showed safety profile similar to placebo; no serious adverse events deemed treatment related.Alder Biopharmaceuticals Inc announces presentation of positive data from phase 2b clinical trial evaluating eptinezumab for prevention of migraine.  Full Article

Alder Biopharmaceuticals reports Q1 loss per share $2.00
Thursday, 27 Apr 2017 04:05pm EDT 

April 27 (Reuters) - Alder Biopharmaceuticals Inc :Alder Biopharmaceuticals announces first quarter 2017 financial and operating results.Q1 loss per share $2.00.Q1 earnings per share view $-0.96 -- Thomson Reuters I/B/E/S.  Full Article

Alder Biopharmaceuticals top-line results from promise 1 expected later this quarter
Monday, 24 Apr 2017 08:30am EDT 

April 24 (Reuters) - Alder Biopharmaceuticals Inc ::Alder Biopharmaceuticals Inc - top-line results from promise 1 expected later this quarter.  Full Article

Alder Biopharmaceuticals reports Q4 loss per share $0.97
Thursday, 23 Feb 2017 04:10pm EST 

Alder Biopharmaceuticals Inc - : Alder Biopharmaceuticals announces fourth quarter and full year 2016 financial and operating results . Q4 loss per share $0.97 .Q4 earnings per share view $-0.90 -- Thomson Reuters I/B/E/S.  Full Article

Alder Biopharmaceuticals posts Q2 loss $0.79/shr
Tuesday, 26 Jul 2016 04:05pm EDT 

Alder Biopharmaceuticals Inc : Alder Biopharmaceuticals reports second quarter 2016 financial and operating results . Q2 shr loss $0.79 . Q2 shr view $-0.75 -- Thomson Reuters I/B/E/S . Alder did not record any revenue in Q2 of 2015 . Net loss for Q2 ended June 30, 2016, totaled $38.9 mln, or $0.79 per share .Q2 shr view $-0.75 -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Alder Biopharmaceuticals Q3 loss per share $0.92

* Alder biopharmaceuticals announces third quarter 2017 financial and operating results